The European Medicines Agency has authorised Pfizer and BioNTech’s updated 2026–2027 COVID-19 vaccine, formulated to target the XFG variant and approved for use from six months of age. Built on BioNTech’s mRNA platform—used in more than five billion doses worldwide—the vaccine showed reassuring safety and a strong antibody response against multiple circulating strains. Production is already under way ahead of fall/winter, and data are being submitted to international health authorities.
EU Approves Pfizer–BioNTech 2026–27 COVID Vaccine Targeting XFG Variant — Cleared For Ages Six Months+
©Vaccine eradicating COVID virus. (Source: Adobe Stock)
European regulators have formally approved Pfizer and BioNTech’s updated 2026–2027 COVID-19 vaccine formulation. The shot is designed to protect against the XFG lineage, which accounted for nearly three-quarters of global infections at its peak in October 2025, and is authorised for use in people aged six months and older.
mRNA Platform and Safety
Built on BioNTech’s proprietary messenger RNA (mRNA) platform, the underlying technology has now been used in more than five billion doses worldwide. The European Medicines Agency (EMA) reviewed clinical data submitted by the partners and concluded that the updated formulation demonstrated reassuring safety outcomes and a robust antibody response against currently circulating strains, including XFG, NB.1.8.1, XFG.1.1, PQ.2.8.1 and PQ.17.
Scope Of Authorisation And Production
The marketing authorisation covers all 27 European Union member states as well as Liechtenstein, Iceland and Norway. According to the EMA announcement, production of the revised formula is already under way to prepare supplies for the coming fall and winter season. Pfizer and BioNTech are also submitting the relevant data packages to international health agencies to support broader regulatory reviews.
Company Context And Market Notes
Pfizer, in operation for more than 175 years, remains a major global biopharmaceutical company focused on expanding access to treatments and advancing medical innovation. Pfizer stock (NYSE: PFE) last traded at US$25.15, up about 3.50% year‑on‑year but down roughly 41.25% since 2021.
BioNTech describes itself as a forward‑looking biopharmaceutical firm developing investigational therapies for cancer and other serious diseases. BioNTech shares (NASDAQ: BNTX) last traded at US$92.95, down about 16.62% year‑on‑year and 71.69% since 2021.
Bottom line: The EMA clearance clears the way for regional distribution of the updated vaccine ahead of the high-transmission season, while both companies continue to share data with international regulators.
Help us improve.
